On June 4, 2020 Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, reported that it was selected by Deciphera Pharmaceuticals as a specialty pharmacy provider for QINLOCKTM (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib (Press release, McKesson, JUN 4, 2020, View Source [SID1234560848]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
QINLOCK, approved by the FDA on May 15, 2020, is for patients who have a significant unmet medical need despite currently available therapies. Because more than 90% of individual metastatic KIT-driven GIST patients experience multiple mutations that cause their disease to progress, this disease is often resistant to existing therapies as they fail to inhibit all known mutations. QINLOCK was designed to inhibit the complete spectrum of known mutations in KIT and platelet-derived growth factor receptor A (PDGFRA).
"We are honored to make this significant new therapy available to GIST patients who have progressed on or are intolerant to established GIST therapies," said Brandon Tom, vice president of Commercial Services for Biologics. "Because we have access to all oral treatments for GIST, the addition of QINLOCK to the Biologics portfolio means we can maintain continuity of care—and even the same care team—for patients who have tried a previous therapy and need to switch to this one."
Biologics specialty pharmacy is committed to and recognized for its quality level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply-skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.
Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.